Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors.

Cell reports - 29 Aug 2023

Mumphrey Michael B, Hosseini Noshad, Parolia Abhijit, Geng Jie, Zou Weiping, Raghavan Malini, Chinnaiyan Arul, Cieslik Marcin

Abstract excerpt

Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histocompatibility Antigens Class I
Share to Histocompatibility Antigens Class II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Immunotherapy and Immune Responses

Share to Mutation

Share to Neoplasms

Share to T-Lymphocytes

Share to vaccines and immunoinformatics approaches

Source

Identifiers

PMID: 37597185
DOI: 10.1016/j.celrep.2023.112965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors.PMID 37597185Read ↗

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumorsSemantic proximity Read ↗

Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics.Semantic proximity Read ↗

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Semantic proximity Read ↗

The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.Semantic proximity Read ↗

Mutant MHC class II epitopes drive therapeutic immune responses to cancer.Semantic proximity Read ↗

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.Semantic proximity Read ↗

A census of predicted mutational epitopes suitable for immunologic cancer control.Semantic proximity Read ↗

The immunogenic potential of recurrent cancer drug resistance mutations: an <i>in silico</i> studySemantic proximity Read ↗

Landscape and functional impact of variants of unknown significance of immune response genes in human cancer.Semantic proximity Read ↗

Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivitySemantic proximity Read ↗

Characterizing MHC-I Genotype Predictive Power for Oncogenic Mutation Probability in Cancer Patients.Semantic proximity Read ↗

Genetic immune escape landscape in primary and metastatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.